[Federal Register: August 14, 2006 (Volume 71, Number 156)]
[Notices]
[Page 46514-46515]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr14au06-94]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 31, 2006, Applied
Science Labs, Division of Alltech Associates Inc., 2701 Carolean
Industrial Drive, State College, Pennsylvania 16801, made application
by renewal to the Drug Enforcement Administration (DEA) to be
registered as a bulk manufacturer of the basic classes
[[Page 46515]]
of controlled substances listed in Schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
4-Methylaminorex (cis isomer) (1590)....... I
Alpha-Ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
2, 5-dimethoxy-4-n)- I
propylthiophenethylamine (2C-T-7) (7348).
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2-5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (AMT) (7432)........ I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-methoxy-N-,N-diisopropyltryptamine (5-MeO- I
DIPT) (7439).
N-Ethyl-1-phenylcyclohexylamine (7455)..... I
1-(1-Phenylcyclohexyl)pyrrolidine (PCPy) I
(7458).
1[1-(2 Thienyl)cyclohexyl] piperidine I
(7470).
Dihydromorphine (9145)..................... I
Normorphine (9313)......................... I
Methamphetamine (1105)..................... II
1-Phenylcylohexylamine (7460).............. II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
1-Piperidinocyclohexanecarbo nitrile (8603) II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Meperidine intermediate-B (9233)........... II
Morphine (9300)............................ II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical application only in clinical, toxicological and forensic
laboratories.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than October 13, 2006.
Dated: July 26, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-13221 Filed 8-11-06; 8:45 am]
BILLING CODE 4410-09-P